BRIEF published on 11/13/2025 at 18:02, 1 month 4 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 1 month 19 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 2 months 18 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 2 months 18 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 2 months 18 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 3 months 20 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 3 months 20 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 5 months ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 5 months ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 5 months 1 day ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
Published on 12/18/2025 at 06:25, 3 hours 25 minutes ago 1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth
Published on 12/18/2025 at 00:55, 8 hours 55 minutes ago Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 9 hours 50 minutes ago Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 10 hours 35 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 18 hours 50 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/18/2025 at 09:36, 13 minutes ago EQS-Adhoc: Intended acquisition of AKH operating company by STRABAG will not take place
Published on 12/18/2025 at 09:30, 19 minutes ago Cembra app now also available to personal loan customers
Published on 12/18/2025 at 09:10, 39 minutes ago Reolink to Preview the Future of AI Security Cameras at CES 2026
Published on 12/17/2025 at 20:39, 13 hours 10 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 18:00, 15 hours 50 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
Published on 12/17/2025 at 17:51, 15 hours 59 minutes ago Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure
Published on 12/17/2025 at 17:50, 16 hours ago The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.
